Latest News and Press Releases

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response...

Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused...

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...

Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...

Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.

Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...

Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...